NCT03837561View on ClinicalTrials.gov

The Efficacy and Safety of CUNOX® in Patients With Moderate to Severe Glabellar Lines

PHASE3CompletedINTERVENTIONAL
Enrollment

136

Participants

Timeline

Start Date

December 13, 2018

Primary Completion Date

March 12, 2019

Study Completion Date

June 3, 2019

Conditions
Glabellar Frown Lines
Interventions
DRUG

Cunox

Inject 4 Units (0.1 mL) of reconstituted investigational product or the comparator intramuscularly into each of 5 sites, 2 in each corrugator muscle and 1 in the procerus muscle for a total dose of 20 Units.

DRUG

Botox

Inject 4 Units (0.1 mL) of reconstituted investigational product or the comparator intramuscularly into each of 5 sites, 2 in each corrugator muscle and 1 in the procerus muscle for a total dose of 20 Units.

Trial Locations (1)

Unknown

Medical Center Capital-Health, Moscow

All Listed Sponsors
lead

Medy-Tox

INDUSTRY

NCT03837561 - The Efficacy and Safety of CUNOX® in Patients With Moderate to Severe Glabellar Lines | Biotech Hunter | Biotech Hunter